Prospective study of immunomodulation with GM-CSF, IL-2, and rituximab following autologous stem cell transplant (SCT) in patients with relapsed lymphomas.

被引：0
|
作者：
Smith, SM
Grinblatt, DL
Gajewski, T
Harlin, H
Welborne, K
Conner, K
Larson, RA
Rich, E
Odenike, O
Zimmerman, T
van Besien, K
机构：
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Northwestern Univ, Evanston, IL USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.918.918
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
918
引用
收藏
页码：263A / 263A
页数：1
相关论文
共 50 条
  • [21] Combination of IFN-alpha/Gm-Csf as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (Asct): a Prospective Phase Ii Study
    Salmasinia, Donya
    Chang, Myron
    Wingard, John R.
    Hou, Wei
    Moreb, Jan S.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2010, 4 : 117 - 125
  • [22] GM-CSF plus IL-2 administration associated with multiple autologous lak reinfusions can induce a major cytogenetic response in early relapsed CML after autologous transplantation: A case report.
    Olivieri, A
    Cantori, I
    Montanari, M
    Provinciali, M
    Di Stefano, G
    Scalari, P
    Scortechini, AR
    Discepoli, G
    Poloni, A
    Mancini, S
    Masia, MC
    BONE MARROW TRANSPLANTATION, 1998, 21 : S65 - S65
  • [23] A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
    Wagner-Johnston, Nina D.
    Goy, Andre
    Rodriguez, Maria A.
    Ehmann, W. Christopher
    Hamlin, Paul A.
    Radford, John
    Thieblemont, Catherine
    Suh, Cheolwon
    Sweetenham, John
    Huang, Yifan
    Sullivan, Sharon T.
    Vandendries, Erik R.
    Gisselbrecht, Christian
    LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2863 - 2869
  • [24] Changes in immunological recovery in patients who received post-transplant G-CSF or GM-CSF after autologous peripheral blood stem cell transplantation (PBSCT)
    Arpaci, F
    Dogru, T
    Ozturk, B
    Komurcu, S
    Ozet, A
    Yilmaz, MI
    Beyzadeoglu, M
    Turan, A
    Sengul, A
    Yalcin, A
    HAEMATOLOGIA, 2002, 32 (03) : 253 - 264
  • [25] Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma
    Henson, M. S.
    Curtsinger, J. M.
    Larson, V. S.
    Klausner, J. S.
    Modiano, J. F.
    Mescher, M. F.
    Miller, J. S.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2011, 9 (02) : 95 - 105
  • [26] High-dose chemotherapy and autologous peripheral blood stem-cell transplantation followed by immunotherapy with GM-CSF and IL-2 in patients with metastatic breast cancer in partial remission. Preliminary results of a phase II study
    Solano, C
    Benet, I
    Marugan, I
    Arbona, C
    Martinez, F
    Hernandez-Boluda, J
    Tormo, M
    Teruel, A
    Terol, M
    Lluch, A
    BONE MARROW TRANSPLANTATION, 2006, 37 : S149 - S149
  • [27] Phase 2 study of interleukin 2 (IL-2) following autologous stem cell transplant (ASCT) for adult patients with acute myelogenous leukemia (AML) in first complete remission (CR).
    Stein, A
    ODonnell, MR
    Lee, J
    Bhatia, R
    Fung, H
    Kashyap, A
    Krishnan, A
    Nademanee, A
    Molina, A
    Margolin, K
    Parker, P
    Planas, I
    Spielberger, R
    Snyder, D
    Smith, E
    Somlo, G
    Slovak, ML
    Vora, N
    Sniecinski, I
    Niland, J
    Forman, SJ
    BLOOD, 1997, 90 (10) : 1699 - 1699
  • [28] Immunotherapy with rituximab/interleukin 2 (IL-2) following autologous peripheral blood stem cell transplant (ASCT) as treatment for CD20 positive now Hodgkin's lymphoma
    Holmberg, L
    Maloney, D
    Gooley, T
    Bensinger, WI
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 116 - 116
  • [29] Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
    Verra, N
    Jansen, R
    Groenewegen, G
    Mallo, H
    Kersten, MJ
    Bex, A
    Vyth-Dreese, FA
    Sein, J
    van de Kasteele, W
    Nooijen, WJ
    de Waal, M
    Horenblas, S
    de Gast, GC
    BRITISH JOURNAL OF CANCER, 2003, 88 (09) : 1346 - 1351
  • [30] Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
    N Verra
    R Jansen
    G Groenewegen
    H Mallo
    M J Kersten
    A Bex
    F A Vyth-Dreese
    J Sein
    W van de Kasteele
    W J Nooijen
    M de Waal
    S Horenblas
    G C de Gast
    British Journal of Cancer, 2003, 88 : 1346 - 1351
12345